The effect of Cytochrome P450 7A1(CYP7A1) polymorphism on lipid responses to simvastatin treatment.
Identifying patients with high-risk of low-response to statin therapy is important for optimization of lipid-lowering therapy. Cholesterol 7α-hydroxylase, a rate-limiting enzyme encoded by Cytochrome P450 7A1(CYP7A1)gene, is considered to be associated with statin efficacy. This study aimed to investigate the association between a novel CYP7A1 single-nucleotide polymorphism (SNP) rs3824260 and statin treatment response for hypercholesteremic patients in Chinese Han population. A total of 336 subjects were prescribed with simvastatin for 12 weeks after enrollment. Plasma lipid parameters were measured at enrollment and after 12-weeks simvastatin treatment separately. Subjects were classified into high- and low-response groups depending on their TC, LDL-C and TG changes, and increase or reduction groups according to their HDL-C levels changing after simvastatin treatment. The CYP7A1 rs3824260 was genotyped from blood samples with a SNaPshot™ assay. At baseline, the LDL-C level and TG level were significantly higher in the AA genotype, while the HDL-C level was significantly higher in the GG genotype of CYP7A1 rs3824260. Patients carrying AA genotype are at an increased risk of low-response for LDL-C reduction (OR=2.295, 95% CI=1.164-4.524, p=0.016). Furthermore, the GG genotype of rs3824260 was significantly associated with a high risk of HDL-C reduction response after simvastatin therapy (OR=2.240, 95% CI=1.137-4.413, p=0.025). The CYP7A1 gene polymorphism rs3824260 is related to inappropriate response of simvastatin treatment for hypercholesterolemia patients in Chinese Han population.